GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » Forward Dividend Yield %

Redhill Biopharma (Redhill Biopharma) Forward Dividend Yield % : 0.00% (As of Apr. 29, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma Forward Dividend Yield %?

As of today (2024-04-29), the Forward Annual Dividend Yield of Redhill Biopharma is 0.00%.

As of today (2024-04-29), the Trailing Annual Dividend Yield of Redhill Biopharma is 0.00%.

RDHL's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.88
* Ranked among companies with meaningful Forward Dividend Yield % only.

Redhill Biopharma's Dividends per Share for the three months ended in Jun. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Redhill Biopharma's Forward Dividend Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redhill Biopharma's Forward Dividend Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's Forward Dividend Yield % falls into.



Redhill Biopharma Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Redhill Biopharma  (NAS:RDHL) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Redhill Biopharma Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Redhill Biopharma (Redhill Biopharma) Business Description

Traded in Other Exchanges
Address
21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.